Literature DB >> 10928508

Angiogenesis in a patient with ischemic limb induced by intramuscular injection of vascular endothelial growth factor and fibrin platform.

N Kipshidze1, V Chekanov, P Chawla, L R Shankar, J B Gosset, K Kumar, D Hammen, J Gordon, M H Keelan.   

Abstract

Direct revascularization of critical ischemia of the limb is often unsuccessful due to the anatomic extent and distribution of arterial occlusive disease, and no pharmacologic treatment has proved effective in treating this condition. Patients with ischemic limb may eventually require amputation and may develop serious morbidity and mortality. The goal of limb salvage in these patients has stimulated research into alternative treatment methods, including angiogenesis. Attempts have been made to apply growth factors directly or to encode DNA for such factors, but it is unknown whether these factors remain at the target site long enough to be effective. We report our strategy of using vascular endothelial growth factor in a fibrin network, which enables the sustained release of biologic material at the target site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928508      PMCID: PMC101055     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  47 in total

1.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.

Authors:  D W Losordo; P R Vale; J F Symes; C H Dunnington; D D Esakof; M Maysky; A B Ashare; K Lathi; J M Isner
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

2.  The sustained release of cefotaxim from a fibrin-cefotaxim compound in treatment of osteitis. Pharmacokinetic study and clinical results.

Authors:  H Zilch; E Lambiris
Journal:  Arch Orthop Trauma Surg       Date:  1986

3.  The use of biologic glue for better adhesions between the skeletal muscle flap and the myocardium and for increasing capillary ingrowth.

Authors:  V Chekanov; V Nikolaychik; G Tchekanov
Journal:  J Thorac Cardiovasc Surg       Date:  1996-03       Impact factor: 5.209

4.  Angiogenic growth factor and revascularization of the ischemic limb: evaluation in a rabbit model.

Authors:  L Q Pu; A D Sniderman; Z Arekat; A M Graham; R Brassard; J F Symes
Journal:  J Surg Res       Date:  1993-06       Impact factor: 2.192

5.  Limb-threatening ischemia in the medically compromised patient: amputation or revascularization?

Authors:  K Ouriel; W M Fiore; J E Geary
Journal:  Surgery       Date:  1988-10       Impact factor: 3.982

6.  Prevention of graft infection by bonding of gentamycin to Dacron prostheses.

Authors:  A Haverich; S Hirt; M Karck; F Siclari; H Wahlig
Journal:  J Vasc Surg       Date:  1992-01       Impact factor: 4.268

7.  Experimental study of intraoperative local chemotherapy with fibrin glue containing nitrosourea for malignant gliomas.

Authors:  M Kabuto; T Kubota; H Kobayashi; T Nakagawa; Y Arai; R Kitai
Journal:  Surg Neurol       Date:  1995-08

8.  Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis.

Authors:  J M Costa; J N Fiessinger; L Capron; M Aiach
Journal:  Thromb Haemost       Date:  1992-02-03       Impact factor: 5.249

9.  High-level expression of recombinant human fibrinogen in the milk of transgenic mice.

Authors:  D Prunkard; I Cottingham; I Garner; S Bruce; M Dalrymple; G Lasser; P Bishop; D Foster
Journal:  Nat Biotechnol       Date:  1996-07       Impact factor: 54.908

10.  Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart.

Authors:  C A Mack; S R Patel; E A Schwarz; P Zanzonico; R T Hahn; A Ilercil; R B Devereux; S J Goldsmith; T F Christian; T A Sanborn; I Kovesdi; N Hackett; O W Isom; R G Crystal; T K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  1998-01       Impact factor: 6.439

View more
  6 in total

1.  A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction.

Authors:  Domenico G Della Rocca; Bradley J Willenberg; Leonardo F Ferreira; Prateek S Wate; John W Petersen; Eileen M Handberg; Tong Zheng; Dennis A Steindler; Naohiro Terada; Christopher D Batich; Barry J Byrne; Carl J Pepine
Journal:  Med Hypotheses       Date:  2012-08-28       Impact factor: 1.538

2.  Fibrin hydrogels for non-viral vector delivery in vitro.

Authors:  Anne des Rieux; Ariella Shikanov; Lonnie D Shea
Journal:  J Control Release       Date:  2009-02-20       Impact factor: 9.776

3.  Cell-responsive hydrogel for encapsulation of vascular cells.

Authors:  Thomas P Kraehenbuehl; Lino S Ferreira; Prisca Zammaretti; Jeffrey A Hubbell; Robert Langer
Journal:  Biomaterials       Date:  2009-06-04       Impact factor: 12.479

Review 4.  A deep dive into the darning effects of biomaterials in infarct myocardium: current advances and future perspectives.

Authors:  Thiagarajan Hemalatha; Mayilvahanan Aarthy; Suryalakshmi Pandurangan; Numbi Ramudu Kamini; Niraikulam Ayyadurai
Journal:  Heart Fail Rev       Date:  2021-08-03       Impact factor: 4.654

5.  VEGF(165) and bFGF protein-based therapy in a slow release system to improve angiogenesis in a bioartificial dermal substitute in vitro and in vivo.

Authors:  I Wilcke; J A Lohmeyer; S Liu; A Condurache; S Krüger; P Mailänder; H G Machens
Journal:  Langenbecks Arch Surg       Date:  2007-04-03       Impact factor: 2.895

6.  In vivo engineering of a human vasculature for bone tissue engineering applications.

Authors:  Lilian Steffens; Andreas Wenger; G Björn Stark; Günter Finkenzeller
Journal:  J Cell Mol Med       Date:  2009-06-28       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.